Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes, "we all know bavi could work in probably ten or twenty other indications."
And when others figure that out we might get a valid valuation model for this company, no thanks to the perennial naysayers.
Bavi in the brain (animule model)
http://ir.peregrineinc.com/releaseDetail.cfm?ReleaseID=423232
Release says the Cancer Research Journal article was published online 11/3.
And here's the 5-day chart from YAHOO:
http://finance.yahoo.com/q/bc?s=PPHMD&t=5d&l=on&z=m&q=l&c=
I wonder if anyone can determine at what time of day the on-line publication appeared.
Does anyone know which Bavi studies, if any, include the option for subjects to continue their treatment after the end of the study period, and what results may be known from the continued therapy?
This NSCLC news hardly seems "over the top."
"Maybe it's just an ego trip."
No doubt.
Look, if hadn't released this PR and they don't get it over $1 in time, you would have said they should have released this (and other) PRs, that by not doing so it shows they really didn't want it to go over $1, and who knows what else.
You know it, I know it, and everyone here knows it.
When the stock starts to move, you'll disappear from this board.
NYT article on cancer drug approval-- personality and process
http://www.nytimes.com/2009/09/16/health/policy/16cancer.html?hp=&pagewanted=print
Plus, the mechanism of action is on features that have been highly conserved through mammalian evolution and almost certainly have not been affected by the comparatively recent changes in genes that produce the different human "races" (so-called) or ethnicities.
Whether credible or creditable, he never had either one.
"standard of care protects physicians from being sued"
and makes them fear being sued if they innovate
Not documented, so not from a credible source. Do you also believe that AIDS came from Fort Detrick?
"September 1991: The USDA denies that any system failures occurred during the hurricane. Whistleblowing workers in Lab 257 at the time of the blackout are fired in further cost-cutting moves and several subsequently develop mysterious undiagnosed diseases."
Care to provide us a link for these speculations?
No, leave quickly
I am holding out for a 256:1 reverse split.
He doesn't understand the difference between the life cycle of the average stock and the life cycle of biotech stocks, or at least he pretends not to.
YYYYYAaaaaaaaawn
"I just quessed that a series of Bavi shots for prevention or treatment might cost $1,000-$5,000."
On the scale contemplated, your numbers seem an order of magnitude too high to me-- maybe more.
Right, old timer. Anything you say, grizzled veteran.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=40508379
"So is what you hear the CC? Just curious."
You have asked a bad-faith question here, and you know it.
He said what he said, he said what you quoted. Your question ignores his words that you yourself quoted. Why?
Why would you think the head of business development should go instead of the head of R&D? You might have a reason, and I'm sure it would edify the board if you disclosed it.
Let's hear your disquisition on the relevant difference between licensee status and assignee status.
Yeah, management and the scientists are just in it for their yearly salary, LOL.
"With about 275 million shares outstanding the short position hasn't been enough to even bother mentioning."
IT MATTERED A MONTH AGO!! http://investorshub.advfn.com/boards/read_msg.aspx?message_id=39453270
Can't you even remember?
"Az, yes H1N1 is an enveloped virus."
As is all flu.
Yeah, I don't doubt (but neither do I know) that it would work against host cells infected with non-envelope viruses, assuming they exhibit the phosphlipid inversion which is the Bavi target. But with non-envelope viruses (I am assuming they don't 'envelop' themselves in the outer membrane from the host cell) the newly budded virus particles themselves might not be subject to attack.
But I'll take an agent that is killer against envelope viruses, and somewhat less effective against non-envelopes, any day of the week.
I wonder if they have checked any viruses that are not envelope viruses.
In response to this:
"what they are really looking for is something to really potentially not just treat the known emerging viruses but new emerging virus that may come up.”
You say: "In other words Bavi didn't do the trick?"
"Do the trick" against new viruses that haven't come up yet?
Moving swiftly on . . . .
If you want to balance BOT posts, trying posting 4 times per year.
YAAAAAWWNN
Does NCB2K refer to:
"Nuclear, Chemical & Biological"
and
"Year 2K"?
All of your posts on PPHM have been today:
http://investorshub.advfn.com/boards/profile.asp?user=160267
This one sets out your strategy:
"buy at 0.65 and below and sell between 1.1 and 1.3 depending upon what the purchase price happened to be. It has worked many times so far."
This one says:
"All I can do is to sell the next time it goes over a $. If it goes below 0.65 I'll buy more."
Your latest says:
"I've already sold my shares --- to make additional monies I need it to go to 0.65 and below where I start buying again"
So tell me, Dauntless, did the price spike up above a dollar today while we weren't looking, or are you a four-flusher?
Your theory may appear to explain the micro-level dynamics of that day's trading, but it doesn't address the reason why there were so many shares traded, nor that it was merely the heaviest day of a run of days during which, in aggregate, a very very large number of shares was traded.
I get the poo part. Who's Mackie?
After you've been here for more than one day, you won't have to ask things like that.
You must be on your way out, your posts are hitting new heights of absurdity.
Yeah, but it's what-- still just above half a percent?
1,280,332/236,96X,XXX Jessmeeeeeee knows by now not to post drivel like that, time you learned.
"orchestrated for the company and financiers"
Weak.
Even for you.
"My guess is it would be."
My guess is it could be.
"Why buy Affitech when they could have been the licensee originally?"
Certain PPHM technology is especially, perhaps uniquely, valuable to Affitech because their developmental programs have been cross-fertilizing each other for years.
Who here knows how much value a license for PPHM's share of the IP behind the jointly-developed R84 would be to someone without Affitech's highly specific and complementary technology?
Maybe even nothing?
No prize this time, but please try again the next time you purchase a PEPSI®!!
"Next prediction: pre-market high will be the high of the day."
Pre-market highs on news are very likely to be the high of the day for many smaller stocks, so you're not risking very much.